Beyond MACE: Semaglutide Significantly Reduces Hospitalization Burden in Patients with Obesity and Cardiovascular Disease
Posted inCardiology Diabetes & Endocrinology news

Beyond MACE: Semaglutide Significantly Reduces Hospitalization Burden in Patients with Obesity and Cardiovascular Disease

This exploratory analysis of the SELECT trial demonstrates that semaglutide 2.4 mg reduces total hospital admissions and total days spent in the hospital by approximately 10-11% in patients with established cardiovascular disease and obesity, highlighting benefits beyond traditional major adverse cardiovascular events.
Targeted Monoclonal Antibody Therapy: Sotrovimab Shows Mortality Benefit in Hospitalized COVID-19 Patients with High Antigen Loads
Posted inInfectious Diseases Internal Medicine news

Targeted Monoclonal Antibody Therapy: Sotrovimab Shows Mortality Benefit in Hospitalized COVID-19 Patients with High Antigen Loads

The RECOVERY trial demonstrates that sotrovimab significantly reduces 28-day mortality in hospitalized COVID-19 patients with high baseline serum antigen levels, highlighting the potential for biomarker-guided monoclonal antibody therapy despite the challenges of evolving viral variants.
Scaling Symptom Relief: EHR-Facilitated Collaborative Care Outperforms Surveillance Alone in Large-Scale Oncology Trial
Posted inHematology-Oncology news Oncology

Scaling Symptom Relief: EHR-Facilitated Collaborative Care Outperforms Surveillance Alone in Large-Scale Oncology Trial

The E2C2 trial demonstrates that integrating electronic health record (EHR)-facilitated collaborative care with symptom surveillance significantly reduces the burden of anxiety, depression, and fatigue in oncology patients compared to surveillance alone, offering a scalable model for population-level symptom management.
GLIAA Trial Results: Contrast-Enhanced MRI Remains the Gold Standard for Re-irradiation Planning in Recurrent Glioblastoma
Posted innews Oncology Radiology

GLIAA Trial Results: Contrast-Enhanced MRI Remains the Gold Standard for Re-irradiation Planning in Recurrent Glioblastoma

The multicenter GLIAA trial demonstrated that FET-PET-guided target volume delineation for re-irradiation does not provide a progression-free survival benefit over standard contrast-enhanced T1-weighted MRI in patients with recurrent glioblastoma, solidifying MRI's role as the preferred clinical delineation method.
The Earlier, the Better: INTERACT Pooled Analysis Confirms 3-Hour Golden Window for Intensive Blood Pressure Lowering in Acute ICH
Posted inEmergency Medicine Neurology news

The Earlier, the Better: INTERACT Pooled Analysis Confirms 3-Hour Golden Window for Intensive Blood Pressure Lowering in Acute ICH

A pooled analysis of over 11,000 patients from the INTERACT trials demonstrates that intensive blood pressure reduction significantly improves functional recovery in acute intracerebral hemorrhage, with the most robust benefits observed when treatment is initiated within three hours of symptom onset.
Smartphone-Based Pulmonary Rehabilitation Bridging the Gap in Chronic Respiratory Care: A Randomized Controlled and Feasibility Study
Posted inFamily Medicine & Nutrition news Respiratory

Smartphone-Based Pulmonary Rehabilitation Bridging the Gap in Chronic Respiratory Care: A Randomized Controlled and Feasibility Study

A randomized trial demonstrates that a smartphone app-based pulmonary rehabilitation program significantly improves quality of life and physical activity in patients with chronic respiratory diseases, offering a scalable alternative to traditional center-based care despite challenges in patient adherence.
Telemedicine is Superior to Onboard Neurologists for Optimizing Mobile Stroke Unit Efficiency: Results from the MSU-TELEMED Trial
Posted inEmergency Medicine Neurology news

Telemedicine is Superior to Onboard Neurologists for Optimizing Mobile Stroke Unit Efficiency: Results from the MSU-TELEMED Trial

The MSU-TELEMED trial demonstrates that a telemedicine model for mobile stroke units significantly improves neurologist resource utilization while maintaining safety, outperforming the traditional onboard neurologist model in a hierarchical composite outcome despite a minor four-minute treatment decision delay.